



European Society of Medical Oncology (ESMO) Congress 2021, Virtual: Eisai Inc. Sponsored Research

Please see the listing of Eisai Inc. sponsored research presented at ESMO Congress 2021 below and refer to the Congress Links section available on our Medical Information website which may include additional information.

RENAL CELL CARCINOMA

1. Choueiri TK, Eto M, Kopyltsov E, et al. Phase 3 CLEAR Trial in Advanced Renal Cell Carcinoma: Outcomes in Subgroups and Toxicity Update. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
2. Rini B, Plimack E, Powles T, et al. Randomized, Open-Label 3-Arm Phase 3 Study of MK-1308A + Lenvatinib and Pembrolizumab (Pembro) + Belzutifan + Lenvatinib versus Pembro + Lenvatinib as First-Line (1L) Treatment for Advanced Clear Cell Renal Cell Carcinoma (ccRCC). Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

HEPATOCELLULAR CARCINOMA

1. Terashima T, Higashibeppu, Yamashita T, et al. Comparison of Medical Costs and Outcome Between Hepatectomy and Radiofrequency Ablation for Hepatocellular Carcinoma. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

ENDOMETRIAL CANCER

1. Colombo N, Lorusso D, Casado Herraes A, et al. Outcomes by Histology and Prior Therapy with Lenvatinib Plus Pembrolizumab vs Treatment of Physician's Choice in Patients with Advanced Endometrial Cancer (Study 309/KEYNOTE-775). Oral presentation at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
2. Makker V, Taylor MH, Aghajanian C, et al. Association Between Biomarkers and Clinical Outcomes of Lenvatinib (L) + Pembrolizumab (P) in Advanced Endometrial Cancer (EC): Results From KEYNOTE-146/Study 111. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

BREAST CANCER

1. Schmidt M, Jackisch C, Hesse T, et al. Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Patients With Locally Advanced or Metastatic Breast Cancer. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
2. Lewis K, Chabot, I, Clayton E, et al. Real World Study of Treatments Received and Treatment Satisfaction Among HER2- Advanced Breast Cancer (ABC) Patients in EU3 and US. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
3. Lewis K, Ndirangu K, Clayton E, et al. Real World Health-related Quality of Life (HRQoL) among HER2-negative (HER2-) Advanced Breast Cancer (ABC) Patients in EU3 and US. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

DIFFERENTIATED THYROID CANCER

1. Taylor MH, Leboulleux S, Panaseykin Y, et al. Health-related Quality-of-Life (HRQoL) Analyses From Study 211 – A Phase 2 Study in Patients (pts) with Radioiodine-Refractory Differentiated Thyroid Cancer Treated With 2 Starting Doses of Lenvatinib (LEN). Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

COLORECTAL CANCER

1. Yoshino, T, Fu R, Hawk N, et al. Pembrolizumab Plus Lenvatinib Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer (mCRC): Phase 3 LEAP-017 Study. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

SOLID TUMORS

1. Yamamoto N, Isa H, Shimizu T, Nakamura Y, et al. Phase 1b Study of a Liposomal Formulation of Eribulin (E7389-LF) + Nivolumab (Nivo) in Patients (pts) with Advanced Solid Tumors. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
2. Kawazoe A, Iwasa S, Koyama T, et al. A Phase 1 Study of E7386, a CREB-Binding Protein (CBP)/ β -Catenin Interaction Inhibitor, in Patients With Advanced Solid Tumors Including Colorectal Cancer (CRC). Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.
3. Doi T, Matsubara N, Naito Y, et al. First-in-Human (FIH) Study of E7130 in Patients (pts) with Advanced Solid Tumors: Primary Result of Dose-Escalation Part. Poster presented

at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

ADDITIONAL STUDIES

1. Ozawa Y, Kuronishi M, Kato Y. The Characterization of Tumors Associated With the Antitumor Activity of Lenvatinib Plus Anti-PD-1 Antibody Combination Therapy in a Mouse Syngeneic Model Panel. Poster presented at the European Society for Medical Oncology (ESMO) Congress; September 16–21, 2021; Virtual.

IMPORTANT INFORMATION - PLEASE READ:

If you would like a full copy of the publication(s) listed above, please submit your request via www.eisaimedicalinformation.com/oncology/medicalinquiry or the submit a Medical Inquiry Form available on our Medical Information website. Please include specific details: Product(s), Poster Number(s), Author(s), Title(s). You may also email your request to Eisai's Medical Information department at esi_oncmedinfo@eisai.com or call 1-888-274-2378.